Eivind Valen Egeland

5PUBLICATIONS
36CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 30, 2026
Systematic interrogation of drug sensitivities in melanoma reveals potent synergistic and antagonistic drug combinations with translational potential.

|Mar 27, 2026
CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts Anti-PD-1 Efficacy in Transgenic Mammary Tumors.

Amanda Poissonnier, Hope S Rugo, Wesley Horton

|Nov 24, 2025
Spatial organization of the tumor-immune microenvironment in ER-positive breast cancer: remodeling during treatment and associations with clinical response.

Maria Aanesland Dahle, Jan-Lukas Førde, Eivind Valen Egeland

|Oct 10, 2024
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.

Eivind Valen Egeland, Kotryna Seip, Eleni Skourti

|Jan 07, 2017
Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer.

Eivind Valen Egeland, Kjetil Boye, Daehoon Park

Pageof 1

Frequent Collaborators

1 joint publications

Kotryna Seip

1 joint publications

Abhilash D Pandya

1 joint publications

Sigve Nakken

1 joint publications

Maria Aanesland Dahle